Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

19.4%

18 terminated/withdrawn out of 93 trials

Success Rate

80.2%

-6.3% vs industry average

Late-Stage Pipeline

25%

23 trials in Phase 3/4

Results Transparency

49%

36 of 73 completed trials have results

Key Signals

36 with results18 terminated

Enrollment Performance

Analytics

Phase 1
41(47.1%)
Phase 2
22(25.3%)
Phase 3
22(25.3%)
Phase 4
1(1.1%)
N/A
1(1.1%)
87Total
Phase 1(41)
Phase 2(22)
Phase 3(22)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (93)

Showing 20 of 93 trials
NCT03837184Phase 3Completed

Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

Role: collaborator

NCT03505099Phase 3Completed

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

Role: collaborator

NCT03444324Phase 3Completed

Adjusted Fibrinogen Replacement Strategy

Role: collaborator

NCT04457076Phase 3Not Yet Recruiting

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Role: collaborator

NCT01144455Phase 2Completed

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Role: collaborator

NCT01550003Phase 3Completed

Pediatric Arthritis Study of Certolizumab Pegol

Role: collaborator

NCT03686683Phase 3Completed

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

Role: collaborator

NCT02454712Phase 1Completed

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

Role: collaborator

NCT01143064Phase 3Completed

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

Role: collaborator

NCT05043766Phase 1Completed

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

Role: collaborator

NCT04974723Completed

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Role: collaborator

NCT05205863Phase 1Completed

Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation

Role: collaborator

NCT04731298Phase 2Terminated

Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Role: collaborator

NCT02523859Phase 3Terminated

Study of the Efficacy and Safety of Remimazolam in General Anesthesia in Adults Undergoing Cardiac Surgery

Role: collaborator

NCT04857840Phase 3Terminated

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

Role: collaborator

NCT02794285Phase 3Completed

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Role: collaborator

NCT02446912Phase 3Completed

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Role: collaborator

NCT02446899Phase 3Completed

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Role: collaborator

NCT04494061Terminated

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

Role: collaborator

NCT02370238Phase 2Completed

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Role: collaborator